skip to Main Content

Neoadjuvant Chemoradiotherapy Extends OS vs. Upfront Surgery in Pancreatic Cancer Subsets

Newsfeed image, light gray text on dark gray background
Neoadjuvant gemcitabine-based chemoradiotherapy prolonged OS compared with upfront surgery among patients with resectable and borderline resectable pancreatic cancer, according to phase 3 study results in Journal of Clinical Oncology.

The optimal chemotherapy regimen for neoadjuvant treatment has not yet been established, but more effective regimens, including FOLFIRINOX (fluorouracil, leucovorin, irinotecan and oxaliplatin), are available, researchers said. Read more . . .


Back To Top